Cervical Cancer, Endometrial Cancer, HER2 Expression, Ovarian Cancer
Conditions
Keywords
Cervical Cancer, Endometrial Cancer, Ovarian Cancer, HER2 Expression, Therapeutic efficacy, Prognosis
Brief summary
This study aims to retrospectively analyze the HER2 expression of gynecological malignant tumors in Chongqing by immunohistochemical detection, and explore the correlation between HER2 level, therapy response and prognosis based on patient clinical information.
Interventions
OTHERno intervention
Since it is a retrospective study, no intervention is needed.
Sponsors
Chongqing University Cancer Hospital
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Patients with primary gynecological malignant tumor confirmed by histopathology * Women aged 18-75 * The expected survival time is greater than 12 weeks * KPS \> 60, ECOG score is 0-2 * All subjects voluntarily joined this study with informed consents, and had good compliance of follow-up
Exclusion criteria
* Pregnant and lactating women * Suffering from other malignant tumors in the past 5 years * Patients who are not suitable for this study according to the investigator's judgment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| HER2 status | from 2023.07 to 2024.05 | HER2 exprssion level evaluated by pathologists |
Contacts
Primary ContactQi Zhou, PH.D
Outcome results
None listed